Ticker

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE THIS RISK-TRANSFER STRUCTURE PROTECTS SHAREHOLDER CAPITAL AND SIGNALS INSTITUTIONAL CONFIDENCE IN THE MASITINIB PROGRAMME AB…

PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH…

Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A.

PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL HEALTH FRANCHISE Paris, February 9, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS)…

PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS UNIQUE AND COMPETITIVE POSITIONING IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DUE TO ITS DISTINCTIVE SAFETY AND EFFICACY PROFILE AND MECANISM OF ACTIONS TARGETING BOTH MICROGLIA AND MAST CELLS Paris, January…